Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB5 gel photodynamic therapy dose and laser-parameter optimization study in cutaneous squamous cell carcinoma in situ
CTR20260668Phase 2Active
- Sponsor
- Zhongke Xianxing Medical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HB5 in Bowen disease (BD), sponsored by Zhongke Xianxing Medical. Started Mar 2026; status: active.
02
Drugs
HB5
03
Conditions
Bowen disease (BD)
Beyond the preview
Go deeper on CTR20260668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260668.